Left main coronary artery thrombosis revealing angio-Behçet syndrome
Jihen Ayari, Mohamed S. Mourali, Abdjalil Farhati, Rachid Mechmeche

Introduction
Behçet’s disease (BD) represents a frequent systemic vasculitis in Japan and Mediterranean basin. It commonly associates buccal and genital ulcers with cutaneous, ocular, neurological, vascular, and gastrointestinal lesions. Although vasculitis represents the anatomic substratum of BD, its presence is not necessary to make diagnosis. In such disease, the incidence of vasculitis varied from 7 to 29% [1], with marked predominance of venous lesions [2]. Coronary involvement was rarely reported [3–5]. Literature data in this regard are scarce; hence, real incidence of coronary occlusion in BD remains unknown. Our article illustrates the management of angio-Behçet, diagnosis of which was made following ST-elevation myocardial infarction (STEMI) secondary to left main thrombosis.

Case report
We report the case of a male patient aged 38 years, without any particular past medical history and having active smoking (10 pack-years) as the only atherosclerosis risk factor. This patient presented in August 2011 with acute and constrictive chest pain evolving since 3 h and highly evocative of infarction scene. Physical examination noted initially stable hemodynamic status without signs of heart failure. On ECG (Fig. 1), ST-segment elevation of about 5 mm in anterior leads and mirror images in inferior leads were noted. This presentation was consistent with the diagnosis of a noncomplicated anterior STEMI seen at the third hour. Given the fact that primary angioplasty was not available at that hour, we immediately opted for pharmacologic revascularization by streptokinase. After fibrinolysis, clinical and electric success criteria were obtained. The course was marked by setting of cardiogenic shock and nonsustained ventricular tachycardia. On transthoracic echocardiography performed in extreme urgency, there were not any mechanical complications. Transthoracic echocardiography showed, however, extended akinesis of the anterior and lateral walls and of the apex without intraventricular thrombus. Left ventricle ejection fraction was estimated at 25%. At the fourth hour and 30th minute, the patient underwent emergency coronary angiography and intra-aortic counterpulsion balloon. The former showed a fresh thrombus floating in the distal part of the left main with TIMI3 flow

Although acute myocardial infarction commonly results from coronary atherothrombosis, there are several other etiologies that should be taken initially into account, especially in young adults without significant atherosclerotic risk factors. Thrombophilia and coronary arteritis are, in this context, examples of etiologies that should be looked after. Through this article, we present a case of Behçet’s disease with arterial involvement diagnosed after myocardial infarction resulting from thrombosis of the left main coronary artery in a 38-year-old young man without any particular past medical history.

Keywords:
behçet’s disease, left main coronary artery, ST-elevation myocardial infarction, thrombolytic therapy, thrombosis

Egypt J Intern Med 26:88–90
© 2014 The Egyptian Society of Internal Medicine
1110-7782

Department of Cardiological Investigations and Resuscitation, La Rabta University Hospital, Tunis, Tunisia
Correspondence to Jihen Ayari, MD, Department of Cardiological Investigations and Resuscitation, La Rabta University Hospital, 1007, Jebbani-Tunis, Tunis, Tunisia Tel: +216 969 96912; e-mail: ayaribermabroukjihen@yahoo.fr
Received 12 April 2014
Accepted 16 April 2014

The Egyptian Society of Internal Medicine
2014, 26:88–90

Figure 1

ECG at the acute phase of myocardial infarction. (a) Elevation of the ST segment in anterior leads (beginning of fibrinolysis). (b) Forty minutes after the beginning of fibrinolysis. (c) Fifty minutes after the termination of fibrinolysis: electric criterion of success.
and clopidogrel), bisoprolol, furosemide, enalapril, and atorvastatin. Clinical course was good; the patient did not develop signs of left heart failure, and repeated echocardiographic controls showed improved and stable left ventricle ejection fraction at 40%.

Discussion

The incidence of vascular involvement in BD varies from 7 to 29% [1]. Cardiac involvement is present in 0.14% of patients [1]. Intraventricular thrombosis, regurgitant valvular heart diseases, coronary arteries aneurysms, and myocardial infarction are some of the reported manifestations of cardiac involvement in such disease [6]. Sporadic cases of granulomatous endocarditis, myocarditis, pericarditis, aortic aneurysms, and conductive tissue disorders were also reported during BD [5].

In such a disease, arterial involvement is less frequent than venous lesions. However, it is markedly more dreadful, as it was correlated to an important morbimortality. There are two types of arterial manifestations: occlusive or more commonly aneurismal lesions, which were noted in 1.5–2.2% of patients [7]. Occlusive and stenotic lesions involve not only great vessels, but also vasa vasorum. Frequently involved arteries in decreasing order are pulmonary artery, femoral, popliteal, subclavian, and carotid arteries. Coronary arteries, particularly the left main coronary artery, are rarely involved. Three forms of coronary arteries involvement during BD were reported: stenosis, thrombosis, and pseudoaneurysms. There are two mechanisms to explain thrombosis during angio-Behçet: vasculitis and hypercoagulable state. BD’s vasculitis involves usually all layers of a vessel and is characterized by the presence of lymphocytic infiltrate during the acute phase. At an advanced stage, an important fibrotic and scarring reaction develops [8,9]. Hypercoagulable state observed during BD is thought to be due to inhibition of fibrinolysis on one hand and due to increased platelet aggregation on the other.

On the seventh day post-STEMI, control coronary angiography showed angiographically healthy and patent coronary arteries (Fig. 3). Etiological investigation did not reveal other atherothrombosis risk factors such as diabetes mellitus or dyslipidemia. Similarly, screening of hyperhomocysteinemia and of anticardiolipin antibodies, anti-\( \beta_2 \) microglobulin-1 antibodies, and protein S, C, and antithrombin deficiencies was negative. Careful questioning and physical examination revealed bipolar ulcers (buccal with a scrotal scar consistent with a sequel of scrotal ulcer), which were highly evocative of BD; hence, it was associated with a positive pathergic test and inflammatory arthralgias. Thoracoabdominopelvic multislice computed tomography scan did not draw evidence of other arterial or venous involvement such as aneurysms or occlusions. There were no signs of uveitis on eye fundus. Given this body of evidence, the diagnosis of angio-Behçet was retained. As a consequence, the patient received, in addition to anti-ischemic medications, colchicine 1 mg/day and bolus of solumedrol for 3 consecutive days. After that, he was put on oral corticotherapy (prednisone) with monthly bolus of cyclophosphamide. The patient was, moreover, under double antiplatelet therapy (acetyl salicylate
hand. The latter had been explained by endothelial dysfunction leading to increased production of von Willebrand factor and decreased levels of prostacyclin (PGI2) [9,10]. Increased production of fibrinogen and factor VIII could also represent other etiological factors explaining hypercoagulable state [11]. In our case, both hypercoagulable state and vasculitis seemed to be involved in coronary occlusion.

In a young patient with almost no significant risk factors of atherosclerosis, etiologies of acute coronary syndrome are, amongst others, coronary embolism, spasm or dissection, and also anomalous coronary arteries. Attention will be focused toward coronary arteritis when there is a particular context of systemic involvement. In our patient, thrombophilia was highly suspected, given angiographically healthy coronary arteries associated with important thrombotic burden in the left main. As biochemical assays performed to search for hyperhomocysteinemia and protein C, S, and antithrombin deficiencies were normal, the discovery of valuable signs evocative of BD allowed us to retain the diagnosis of angio-Behçet according to the reported criteria by the international study group for BD [12].

As cases are scarce, optimal therapeutic alternative in case of coronary thrombosis during BD remains unknown. Some authors suggested, however, that primary angioplasty was the most recognized revascularization option during STEMI secondary to BD's coronary thrombosis [13–15]. Nevertheless, long-term results after successful angioplasty and stent implantation remain unknown [16]. According to Ando et al. [17], coronary bypass grafting was not considered the best therapeutic option, as it was associated with postoperative coronary pseudoaneurysms. In our patient, in whom BD was unknown at admission, pharmacologic revascularization was undertaken at the acute phase of STEMI and was effective as demonstrated by the clinical and electric criteria on one hand and by angiographic findings (TIMI 3 flow) on the other hand. Given the marked thrombotic burden in the left main, anti-GpIIb–IIIa (tirofiban) was given. Similarly, other successful cases of fibrinolysis were reported [18] in addition to efficiency of anti-GpIIb–IIIa [19], which was, in preference, indicated in case of fresh thrombus floating in coronary arteries without delayed flow or need for emergent revascularization. Moreover, according to the case reported by Ergelen et al. [20] illustrating left main thrombosis with stable hemodynamic status in a patient suffering from BD, successful fibrinolysis followed by the use of anti-GpIIb–IIIa had proved effective as demonstrated by further coronary angiography showing patent coronary arteries. Because of the arterial involvement, BD was considered severe in our patient justifying initial intravenous corticotherapy followed by oral corticoids and cyclophosphamide. Nevertheless, although steroidal anti-inflammatory drugs could spare the patient from further outbreaks, such treatment could not only accelerate atherosclerosis process, but also increase the risk for cardiac decompensation. Hence, although the immediate course appears to be good, medium and long-term prognosis remain reserved.

Acknowledgements

Conflicts of interest

There are no conflicts of interest.

References

1. Gurler A, Boyvat A, Tursen U. Clinical manifestations of Behçet’s disease: an analysis of 2147 patients. Yonsei Med J 1997; 38:423–427.
2. Kabbaj N, Benjellou G, Gueddari FZ, Dafri R, Imami F. Vascular involvements in Behçet’s disease. Based on 40 patient records. J Radiol 1993; 74:649–656.
3. Blotery O, Mohatane A, Wechster B, Beaufils P, Valere P, Petit J, et al. Cardiac involvement in Behçet’s disease. Presse Med 1996; 17:2388–2391.
4. Wechster B, Du LT, Kieffer E. Cardiovascular manifestations of Behçet’s disease. Ann Med Interne 1999; 150:542–554.
5. Bowles CA, Nelson AM, Hammill SC, O’Duffy JD. Cardiac involvement in Behçet’s disease. Arthritis Rheum 1985; 28:345–348.
6. Basaran Y, Dergicelik M, Direskeneli H, Yakut C. Cardiac thrombosis in a patient with Behçet’s disease: two years follow-up. Int J Card Imaging 2000; 16:377–382.
7. Iscan ZH, Vural KM, Bayazit M. Compelling nature of arterial manifestations in Behçet disease. J Vasc Surg 2005; 41:53–58.
8. Ko GY, Byun JY, Choi BG, Cho SH. The vascular manifestations of Behçet’s disease: angiographic and CT findings. Br J Radiol 2000; 73:1270–1274.
9. Hamza M. Maladie de Behçet. In: Kahn MF, Pelletier AP, Meyer O, Piette JC, editors. Maladies et syndromes systémiques. 4th ed. Paris: Flammarion Médecine-Sciences; 2000. 863–924.
10. Özorar K, Düzgün N, Güler A, Yutuk H, Tokgöz G. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet’s disease. Scand J Rheumatol 1995; 24:376–382.
11. Hutchison SJ, Belch JJ. Behçet’s syndrome presenting as myocardial infarction with impaired blood fibrinolysis. Br Heart J 1984; 52:686–687.
12. [No authors listed]. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s disease. Lancet 1990; 335:1078–1080.
13. Drobiniski G, Wechster B, Pavie A, Artigou JY, Marek P, Godeau P. GROSSE E. Emergency percutaneous coronary dilation for acute myocardial infarction in Behçet’s disease. Eur Heart J 1987; 8:1133–1136.
14. Tamura Y, Matsuoka A, Ohtani E, Okabe M, Shibata A. Behçet’s disease complicated by acute myocardial infarction treated with percutaneous transluminal coronary angioplasty. Kokyu To Junkan 1988; 36:341–346.
15. Erbilten E, Albayrak S, Gucukan E, Taser F, Bulur S, Ozhan H, Yazici M. Acute coronary stenosis in a young man with Behçet’s syndrome. Med Princ Pract 2008; 17:157–160.
16. Tezcan H, Yavuz S, Fak AS, Aker U, Direskeneli H. Coronary stent implantation in Behçet’s disease. Clin Exp Rheumatol 2002; 20:704–706.
17. Ando M, Kosakai Y, Okita Y, Nakano K, Kitamura S. Surgical treatment of Behçet’s disease involving aortic regurgitation. Ann Thorac Surg 1999; 68:2136–2140.
18. Kosar F, Sahin I, Gullu H, Cehreli S. Acute myocardial infarction with normal coronary arteries in a young man with the Behçet’s disease. Int J Cardiol 2005; 99:355–357.
19. Nurkalem Z, Ussl N, Gorgulu S, Eren M. Left main coronary thrombosis with essential thrombocythemia. J Thromb Thrombolysis 2006; 22:165–167.
20. Ergelen M, Soyolu U, Uyarel H, Yildirim A, Osonov D, Ohan AL. Management of acute coronary syndrome in case of Behçet’s disease. Blood Coagul Fibrinolysis 2009; 20:715–718.